6533b86dfe1ef96bd12ca930

RESEARCH PRODUCT

Continuous neurophatic orofacial pain: a retrospective study of 23 cases

Dídac Sotorra-figuerolaAlba Sánchez-torresCosme Gay-escodaEduard Valmaseda-castellon

subject

Orofacial painmedicine.medical_specialtyOrofacial painDolor facialFacial painPopulationOdontologíaOrofacial pain-TMJD03 medical and health sciences0302 clinical medicinemedicineAmitriptylineFacial paineducationGeneral Dentistryeducation.field_of_studybusiness.industryResearchRetrospective cohort study030206 dentistryBurning mouth syndrome:CIENCIAS MÉDICAS [UNESCO]DermatologyCiencias de la saludClonazepamLate diagnosisEstudi de casosUNESCO::CIENCIAS MÉDICASPhysical therapyCase studiesmedicine.symptombusinessDolor orofacial030217 neurology & neurosurgerymedicine.drug

description

Background To determine the clinical characteristics of Continuous Neuropathic Orofacial Pain in patients that suffer Persistent Idiopathic Facial Pain (PIFP), Painful Post-Traumatic Trigeminal Neuropathy (PPTTN) or Burning Mouth Syndrome (BMS) and to describe their treatment. Material and Methods A retrospective observational study was made, reviewing the clinical history of the patients diagnosed with Continuous Neuropathic Orofacial Pain between 2004 and 2011 at the Orofacial Pain Unit of the Master of Oral Surgery and Implantology of the University of Barcelona and at the Orofacial Pain Unit of the Teknon Medical Center of Barcelona. Results The average age of the patients with Continuous Neuropathic Orofacial Pain was 54.5, with a clear female predominance (86.9%, n=20). Of all patients, 60.9% (n=14) were suffering a PIFP, 21.7% (n=5) had a BMS and 17.4% (n=4) were presenting a PPTTN. The pain quality described by the patients with Continuous Neuropathic Orofacial Pain was oppressive (43.47%, n=10), widely represented by patients with PIFP, and burning (39.13%, n=9) being the only quality that described patients with BMS. The treatment carried out with the patients was only pharmacologic. The most used drugs for the treatment of PIFP and PPTTN were clonazepam (50%, n=9) and amitriptyline (44.44%, n=8). However, a 55.5% (n=10) of the patients with PIFP or PPTTN required the association of two or more drugs for a correct pain control. All the patients with BMS responded satisfactorily to clonazepam. Conclusions Continuous Neuropathic Orofacial Pain is a little known condition among the general population, physicians and dentists. This favors a late diagnosis and inaccurate treatments which entail unnecessary suffering. It is important to inform both the general population and health professionals concerning this painful condition. Key words:Continuous neuropathic orofacial pain, persistent idiopathic facial pain, painful post-traumatic trigeminal neuropathy, burning mouth syndrome, atypical odontalgia.

10.4317/jced.52560http://hdl.handle.net/2445/158647